Vol.

No.

January 05, 2024Jan 05, 2024

DOWNLOAD THE PDF

CMS starts paying for patient navigation; ACS offers navigation credentialing program

Cover Story

Conversation with The Cancer Letter Free

CMS starts paying for patient navigation; ACS offers navigation credentialing program

By Paul Goldberg and Jacquelyn Cobb

Medicare has started to pay for navigation for guiding patients through the maze of health care services in settings where treatment involves multiple specialties.

Guest Editorial

How Delaware became a model for improving cancer control, prevention, and treatment

By Nicholas J. Petrelli

Free Obituary

Sidney Wolfe, father of “research-based advocacy,” dies at 86

By Alexandria Carolan

Editorial Free

The Cancer Letter turns 50
Documenting half a century of cancer progress

By Katie Goldberg

Free In the Archives

60 years after: Don Shopland and Alan Blum discuss the writing of the 1964 Surgeon General’s Report on Smoking and Health

By Alexandria Carolan

In Brief

W. Kimryn Rathmell installed as 17th NCI director

Eric Small elected ASCO president for 2025-2026 term

2024 ASCO board of directors and nominating committee members elected

David Linehan named CEO of University of Rochester Medical Center

Kristin Heath named executive director of the UF Health Proton Therapy Institute

Ramez Eskander named director of CTO at UCSD Moores Cancer Center

David Swoboda named clinical director of Leukemia Program at TGH Cancer Institute

Convergent Science Cancer Consortium receives $3.2M grant from DoD

UNM CCC breaks ground on $61M expansion

Nationwide Children’s Hospital and OSUCCC—James open proton therapy center opens

Baylor’s culinary event raises $6.2 million for cancer research

Clinical Roundup

Community cancer care linked with poorer outcomes for some head/neck cancers

Novel liquid biopsy of lymph fluid could guide precision treatment for head and neck cancer

Jemperli + Zejula improved PFS in advanced or recurrent endometrial cancer in RUBY Part 2 phase III trial

Inavolisib combination demonstrates 57% PFS in breast cancer indication

Kadcyla demonstrates OS benefit in breast cancer indication

Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

CAR T-cell therapy for T-cell lymphoma shows promise in phase I study

Drugs & Targets

FDA approves Welireg for advanced renal cell carcinoma

FDA approves Padcev + Keytruda for locally advanced or metastatic urothelial cancer

European Commission authorizes Jemperli plus chemo in endometrial cancer indication

Infinimmune, Grid Therapeutics form partnership for deep sequencing of B cells for NSCLC drug discovery

Elektrofi, Janssen Biotech form collaboration

NCI Trials

NCI Trials for January 2024

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 42 - November 08, 2024